Company profile: Contera Pharma
1.1 - Company Overview
Company description
- Provider of drug discovery and development focused on innovative treatments for movement disorders, collaborating with expert individuals and organizations. Lead program JM-010 combines immediate-release buspirone and extended-release zolmitriptan to treat dyskinesia associated with dopamine replacement therapies in Parkinson’s disease.
Products and services
- Collaboration-Driven Drug Discovery: Identifies innovative movement disorder treatments using expert drug discovery capabilities in close collaboration with individuals and organizations, establishing foundations for success
- Expert-Guided Therapeutic Development: Develops innovative treatments for patients suffering from movement disorders through applied expertise in drug development and coordinated work with expert individuals and organizations to deliver foundations for success
- JM-010: Phase IIa-approved combination therapy employing immediate-release buspirone and extended-release zolmitriptan to mitigate dyskinesia associated with dopamine replacement therapies in Parkinson’s disease patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Contera Pharma
Neurofluidics
HQ: United States
Website
- Description: Provider of organs-on-chip and microfluidic medical devices that reproduce in vitro neuronal networks up to connectome-on-chip, enabling study of human organ physiology, drug effects, and molecular and functional mechanisms on neuronal circuits. Offerings include MEA-integrated devices for recording neural activity (developed with Axion BioSystems), UpLink software, and models such as innervated skin, pain-on-chip, and DuaLink for chemotherapy studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurofluidics company profile →
Satsuma Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development for migraine, advancing STS101, a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine (DHE) for the acute treatment of migraine, self-administered via a pre-filled, single-use nasal delivery device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satsuma Pharmaceuticals company profile →
Alliance
HQ: United States
Website
- Description: Provider of in-home neurodiagnostic testing services, including video EEG testing and remote EEG monitoring, as well as cardiac monitoring solutions such as mobile cardiac telemetry, extended Holter testing, and event monitoring, plus cloud-based EEG software for secure access to EEG data and synchronized review of EEG and video recordings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alliance company profile →
Helius Medical
HQ: United States
Website
- Description: Provider of neurotechnology for neurological wellness, offering PoNS Therapy, a program combining the PoNS device with physical therapy to improve gait and balance deficits in patients with neurological conditions, and the PoNS Device, a non-implantable device delivering mild electrical tongue stimulation to promote neuroplasticity and improve motor function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helius Medical company profile →
Tonix Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical products focused on central nervous system disorders, including TNX-102 SL sublingual tablet for fibromyalgia, Long COVID and acute stress disorder; TNX-1500 anti-CD40L antibody for transplant rejection and autoimmune conditions; TNX-801 live horsepox vaccine for smallpox/monkeypox; TNX-2900 intranasal oxytocin for Prader-Willi syndrome; TNX-1700 for gastric/colorectal cancers; and TNX-1300 for cocaine overdose.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tonix Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Contera Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Contera Pharma
2.2 - Growth funds investing in similar companies to Contera Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Contera Pharma
4.2 - Public trading comparable groups for Contera Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →